CTLA4 and neoplasm: In 32 paired tumor biopsies taken at baseline and two weeks after treatment initiation in a randomized phase II study of stereotactic body radiotherapy of a liver metastasis and immunotherapy (with either PD-1- or combined PD-1- and CTLA-4-blockade), only a minority demonstrated an increase in tumor-associated immune cells.